First Wave BioPharma, Inc.’s interview with James Sapirstein, Chairman, CEO & President

Click the Subscribe button for the latest in crypto, blockchain and business news from NEW TO THE STREET!

#crypto #cryptocurrency #blockquake #blockchain #blockchainnews #digitalcurrency #newtothestreet #janeking #exploringtheblock #foxbusinessnews #foxbusiness #financialnews #businessnews #ai #newsmaxtv #FirstWaveBioPharm

New to The Street TV, in-studio at NASDAQ, interviews Mr. James Sapirstein, Chief Executive Officer at First Wave BioPharma, Inc. (NASDAQ:FWBI) (formerly known as AzurRX BioPharma, Inc.), a clinical-stage biopharmaceutical Company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Mr. Sapirstein provides TV Host Jane King a comprehensive update on corporate on-goings, and he explains why they did a name change. He talks about new drug data regarding ulcerative proctitis as it relates to colitis. The Company has 4 active Phase II FDA trials, and he explains the process and progress of each. James talks about niclosamide, and the anticipate results in forthcoming trials as an oral medication for the treatment of COVID-19. In conclusion, James explains that being first-market with an oral COVID treatment could be a game-changer for the world and for the Company.

To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/channel/UCceRKKS0QUfXlKUPBoxdTHQ

Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://newtothestreet.com/

Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list